关于收到北京证券交易所对公司年报问询函的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：833266 证券简称：生物谷 公告编号：2024-051 云南生物谷药业股份有限公司 云南生物谷药业股份有限公司（以下简称"公司"）于 2024 年 5 月 10 日收到北京证券交易所上市公司管理部下发的《关于对云南生 物谷药业股份有限公司的年报问询函》（年报问询函【2024】第 006 号）（以下简称"《问询函》"），现将《问询函》内容公告如下： "云南生物谷药业股份有限公司（生物谷）董事会并信永中和会计师 事务所（特殊普通合伙）： 我部在对你公司 2023 年年度报告事后审查中关注到以下情况： 1、关于经营业绩 报告期内，你公司营业收入为 62,233.87 万元，同比增长 5.96%； 本期综合毛利率为 80.94%，同比下降 0.16 个百分点。分产品类别看， 你公司灯盏生脉胶囊营业收入为 37,497.07 万元，同比增长 2.36%， 毛利率 78.36%，同比下降 0.74 个百分点； ...

关于对云南生物谷药业股份有限公司的 年报问询函 年报问询函【2024】第 006 号 云南生物谷药业股份有限公司（生物谷）董事会并信永中和会计师 事务所（特殊普通合伙）： 我部在对你公司 2023 年年度报告事后审查中关注到以下情况： 1、关于经营业绩 报告期内，你公司营业收入为 62,233.87 万元，同比增长 5.96%； 本期综合毛利率为 80.94%，同比下降 0.16 个百分点。分产品类别看， 你公司灯盏生脉胶囊营业收入为 37,497.07 万元，同比增长 2.36%， 毛利率 78.36%，同比下降 0.74 个百分点；灯盏细辛注射液营业收入 为 23,223.24 万元，同比增长 12.53%，毛利率 89.53%，同比增长 0.29 个百分点。公司销售区域包括 9 个大区，其中第一大区华南区 域实现销售收入 1.06 亿元，毛利率为 70.24%，其他区域的毛利率均 超过 80%。 2022 年度、2023 年度，你公司归属于上市公司股东的净利润分 别为-4,891.12 万元、-1,220.02 万元，亏损原因主要是对尚未全部 归还的资金占用款计提坏账准备，金额分别为 8,995 万元、 ...

Financial Performance - Net profit attributable to shareholders for Q1 2024 was CNY 10,529,264.31, representing a significant increase of 510.18% year-over-year[12] - Operating revenue for the first quarter of 2024 was CNY 154,441,052.85, reflecting a growth of 13.71% compared to the same period last year[12] - The company reported a basic earnings per share of CNY 0.08, up 700.00% from CNY 0.01 in the previous year[12] - The company’s total profit for Q1 2024 was CNY 13,247,437.80, an increase of 363.11% year-over-year[14] - The company reported a total comprehensive income for Q1 2024 of CNY 10,529,264.31, significantly higher than CNY 1,725,600.86 in Q1 2023, indicating a growth of approximately 510.5%[55] - The company's total profit for Q1 2024 was CNY 11,936,052.62, compared to CNY 1,249,419.76 in Q1 2023, representing an increase of about 855.5%[58] Cash Flow and Liquidity - The company's cash flow from operating activities increased by 21.17% to CNY 54,184,916.38 in Q1 2024[12] - The total cash and cash equivalents at the end of Q1 2024 reached CNY 205,555,244.94, up from CNY 155,106,733.08 on December 31, 2023, reflecting a growth of approximately 32.5%[47] - The net cash flow from operating activities for Q1 2024 was CNY 53,899,687.30, a significant increase from CNY 16,870,605.76 in Q1 2023, reflecting improved operational efficiency[64] - The company reported a net increase in cash and cash equivalents of CNY 53,522,401.85 for Q1 2024, compared to an increase of CNY 2,318,861.37 in Q1 2023, indicating strong cash generation[64] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 1,245,010,150.21, an increase of 0.75% compared to the end of 2023[12] - The total liabilities to assets ratio for the consolidated entity was 18.87%, a slight decrease from 19.12% at the end of 2023[12] - The company's total liabilities decreased to CNY 235,002,635.69 as of March 31, 2024, from CNY 236,223,971.63 on December 31, 2023, showing a reduction of approximately 0.5%[49] - The company's total equity increased to CNY 1,010,007,514.52 as of March 31, 2024, compared to CNY 999,478,250.21 on December 31, 2023, marking an increase of about 1.6%[49] Shareholder Changes and Legal Issues - The original controlling shareholder, Shenzhen Jinsanjian Investment Co., Ltd., held 30,000,000 shares (24.19% of total shares) before the judicial auctions[22] - After the auctions, the new controlling shareholder is Shanghai Xinhong, which acquired 32,851,219 shares (26.49% of total shares) from the original shareholders[23] - The company has initiated a civil lawsuit against Jinsanjian for a fund occupation balance of 257 million yuan[29] - The company received a notice from the Shenzhen Intermediate People's Court regarding a lawsuit involving Lin Yanhe and others, with the case accepted on August 17, 2022[30] - The original controlling shareholder, 金沙江, occupied funds totaling ¥257 million, with repayments of ¥39.06 million and ¥39.70 million made in 2021 and early 2022 respectively[34] Research and Development - Research and development expenses decreased by 41.95% to CNY 2,782,072.88 compared to the same period last year[14] - Research and development expenses decreased to CNY 2,697,325.40 in Q1 2024 from CNY 4,792,473.34 in Q1 2023, a reduction of approximately 43.7%[58] Inventory and Receivables - The company’s inventory decreased to CNY 98,256,192.51 as of March 31, 2024, down from CNY 108,244,983.82 on December 31, 2023, representing a decline of approximately 9.1%[47] - The company’s accounts receivable decreased to CNY 118,579,931.49 as of March 31, 2024, compared to CNY 131,839,929.98 on December 31, 2023, indicating a decrease of about 10%[47]

Product Development and Recognition - In January 2023, the company's product, Dengzhanhua Capsule, was included in the expert consensus on the scientific prevention and treatment of infectious diseases in the elderly and children by the China Association of Traditional Chinese Medicine[5]. - In June 2023, the company was listed in the "Top 100 Chinese Traditional Medicine Enterprises" for 2022, and its Dengzhanhua Capsule and Dengzhanhua Injection were included in the "Guidelines for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine" published by the Chinese Association of Traditional Chinese Medicine[7]. - The company won the second prize of the National Education Ministry's Science and Technology Progress Award for the project on the evidence-based evaluation and application promotion of integrated prevention strategies for ischemic stroke, completed in collaboration with Guangzhou University of Chinese Medicine[7]. - In October 2023, the company's subsidiary "Biovalley" brand Dengzhanhua was selected for the "2023 Yunnan Province Green Cloud Product Brand" directory[8]. - The company focuses on the research, production, and marketing of traditional Chinese medicine, with key products including Dengzhanhua series products such as Dengzhanhua Capsule and Dengzhanhua Injection[22]. Financial Performance - The company's operating revenue for 2023 was approximately ¥622.34 million, representing a year-over-year increase of 5.96% compared to ¥587.34 million in 2022[34]. - The net profit attributable to shareholders of the listed company for 2023 was approximately -¥12.20 million, a significant improvement of 75.06% from -¥48.91 million in 2022[34]. - The company’s total assets at the end of 2023 were approximately ¥1.24 billion, a decrease of 0.61% from ¥1.24 billion at the end of 2022[36]. - The company’s total liabilities increased by 2.00% to approximately ¥236.22 million in 2023, compared to ¥231.58 million in 2022[36]. - The gross profit margin for 2023 was 80.94%, slightly up from 80.78% in 2022[34]. Cash Flow and Investments - The company’s cash flow from operating activities improved significantly to approximately ¥114.69 million in 2023, compared to -¥90.50 million in 2022, marking a 226.72% increase[36]. - The company invested ¥65 million during the reporting period, representing a 56.63% increase compared to ¥41.5 million in the same period last year[89]. - Cash and cash equivalents increased by 39.98% to ¥155,106,733.08, primarily due to an increase in sales collections of ¥90.43 million[66]. Research and Development - R&D expenses increased by 30.97% to ¥20,130,564.61, driven by the addition of three outsourced R&D projects[72]. - The company has established a patent management system to enhance its intellectual property capabilities and support high-quality development in the "Dengzhanhua" industry[52]. - The company has three ongoing R&D projects aimed at enhancing product capabilities and exploring new uses, which are expected to improve clinical value and market competitiveness[104]. Market Strategy and Expansion - The company plans to actively expand sales channels and accelerate new product development in response to price adjustments for its product, Dengzhanxixin injection[30]. - The company aims to enhance its market presence by focusing on key markets and integrating marketing resources to achieve sales growth in 2023[51]. - The company plans to strengthen cooperation with high-level research institutions to enhance the secondary development of existing products and academic achievement transformation[63]. Compliance and Governance - The company has engaged Xinyong Zhonghe Accounting Firm for auditing, which issued a qualified audit report for the financial statements[12]. - The company is committed to maintaining compliance in its marketing practices and expanding its sales channels, including OTC retail[49]. - The company is actively addressing fund occupation issues through legal compliance and communication with relevant parties[60]. Shareholder and Ownership Changes - The company is controlled by Shenzhen Jinsanjiang Investment Co., Ltd[23]. - The company’s controlling shareholder changed from Jins江 to Shanghai Xinhong after two judicial auctions, with the new controlling shareholders being Luo Cheng, Lin Hongli, Lin Hongyuan, and Wang Rui[27]. - The total share capital of the company is now 124,000,007 shares after a reduction of 3,999,993 shares[182]. Risks and Challenges - The company faces risks from industry policy changes that may affect its operational strategies and market conditions[136]. - The company faces potential price reduction risks due to participation in centralized procurement and bidding, which may impact future growth and product gross margins[141]. - The company has recognized a bad debt provision of CNY 133.64 million due to the outstanding funds occupied by the controlling shareholder, which amounts to CNY 257 million[168].

国新证券股份有限公司 关于云南生物谷药业股份有限公司的风险提示性公告 国新证券股份有限公司（以下简称"国新证券"、"保荐机构"）作为云南生 物谷药业股份有限公司（以下简称"生物谷"、"公司"）的保荐机构，通过持续 督导及定期报告事前审核，发现公司存在以下情况： 一、风险事项基本情况 （一）风险事项类别 | 序号 | 类别 | 风险事项 | 公司是否履行信 | | --- | --- | --- | --- | | | | | 息披露义务 | | 1 | 公司治理 | 原控股股东占用公司资金 | 是 | | 2 | 其他 | 财务报告被出具保留意见 | 是 | （二）风险事项情况 1、公司原控股股东存在占用公司资金的情况： 公司原控股股东深圳市金沙江投资有限公司（以下简称"金沙江投资公司"） 通过生物谷公司对第三方背书银行承兑汇票的方式占用公司资金，其中 2021 年 度占用资金 67,115,237.50 元，归还资金 39,061,315.34 元，2022 年 1 月份占用资 金 11,649,139.54 元，归还资金 39,703,061.70 元；金沙江投资公司通过生物谷委 托第三方理财的方式占用公 ...

云南生物谷药业股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 3 | 信永中和会计师事务所| 北京市东城区朝阳门北大街| telephone: 8 号富华大厦 A 座 9 层 联系电话:+86(010)6554 2288 +86 (010) 6554 2288 ShineWing certified public accountants onacheng District. Beijing 关于云南生物谷药业股份有限公司 2023 年度非经营性资金占用及其他关联资金在来的专项说明 XYZH/2024SZAA8F0226 云南生物谷药业股份有限公司 云南生物谷药业股份有限公司全体股东: 我们按照中国注册会计师审计准则审计了云南生物谷药业股份有限公司(以下简称生 物谷公司)2023年度财务报表,包括 2023年12月 31 日的合并及母公司资产负债表、2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变动表以 及财务报表 ...

关于云南生物谷药业股份有限公司 2023 年度营业收入扣除情况的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 2023 年度营业收入扣除情况表 | 3 | 关于云南生物谷药业股份有限公司 2023 年度营业收入扣除情况的专项说明 XYZH/2024SZAA8F0225 云南生物谷药业股份有限公司 云南生物谷药业股份有限公司全体股东: 我们按照中国注册会计师审计准则审计了云南生物谷药业股份有限公司(以下简称 生物谷公司)2023年度财务报表,包括2023年12月31日的合并及母公司资产负债表、2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变动表, 以及相关财务报表附注,并于2024年4月28日出具了XYZH/2024SZAA8B0323号保留意见的 审计报告。 联系电话: 信永中和会计师事务所|北京市东城区朝阳门北大街 8 号富华大厦 A 座 9 层 telephone: certified public accountants No 8 Chaovangmen Beidaiie ngcheng District, Beiji ...

证券代码：833266 证券简称：生物谷 公告编号：2024-031 云南生物谷药业股份有限公司 关于确认 2023 年度关联交易的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、关联交易概述 （一）关联交易概述 1、公司第四届董事会第十二次会议、第四届监事会第八次会议 及 2022 年第五次临时股东大会审议通过《关于深圳分公司向关联方 租赁房屋的议案》，深圳分公司拟向关联方深圳市金沙江投资有限公 司（以下简称"金沙江"）租赁其位于深圳市福田区益田路江苏大厦 A 栋 34 层的 3402 号房屋并搬迁至此地办公，租赁期限一年。房屋租 赁面积为 302.12 平方米，租金每平方米 157 元，月租金为人民币 47,432 元，一年租金总额为 569,184 元。 2、公司第四届董事会第十五次会议及第四届监事会第十次会议 审议通过《关于审议 2023 年日常性关联交易预计的议案》，预计 2023 年本公司及子公司与关联方发生日常性关联交易总额不超过 110 万 元的关联交易，包括但不限于以下情形： ...

云南生物谷药业股份有限公司 ᇗ䇗ᣛ ;<=+6=$$% Ӂই⭏⢙䉧㦟ъ㛑ԭᴹ䲀ޜਨ Ӂই⭏⢙䉧㦟ъ㛑ԭᴹ䲀ޜਨޘփ㛑ь˖ 2023 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-5 | | 公司财务报表 | | | | — | 合并资产负债表 | 6-7 | | — | 母公司资产负债表 | 8-9 | | — | 合并利润表 | 10 | | — | 母公司利润表 | 11 | | — | 合并现金流量表 | 12 | | — | 母公司现金流量表 | 13 | | — | 合并股东权益变动表 | 14-15 | | — | 母公司股东权益变动表 | 16-17 | | — | 财务报表附注 | 18-97 | аǃ ؍⮉㿱 | | | --- | ᡁԜᇑ䇑ҶӁই⭏⢙䉧㦟ъ㛑ԭᴹ䲀ޜਨ˄ԕлㆰ〠⭏⢙䉧ޜਨ˅䍒࣑ᣕ㺘ˈवᤜ ᒤ ᴸ ᰕⲴਸᒦ৺⇽ޜਨ䍴ӗ䍏٪㺘ˈ ᒤᓖⲴਸᒦ৺⇽ޜਨ࡙⏖㺘ǃਸᒦ ৺⇽ޜਨ⧠䠁⍱䟿㺘ǃਸᒦ৺⇽ޜਨ㛑ьᵳ⳺ਈࣘ㺘ˈԕ৺ޣ䍒࣑ᣕ㺘䱴⌘DŽ ᡁԜ䇔Ѫˈ䲔Āᖒᡀ؍⮉㿱Ⲵสā䜘࠶ᡰ䘠һ亩ਟ㜭ӗ⭏Ⲵᖡ૽ཆˈਾ䱴Ⲵ䍒࣑ ᣕ㺘൘ᡰᴹ䟽 ...

证券代码：833266 证券简称：生物谷 公告编号：2024-035 云南生物谷药业股份有限公司 关于会计师事务所 2023 年度履职情况评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 云南生物谷药业股份有限公司（以下简称"公司"）聘请了信永 中和会计师事务所（特殊普通合伙）（以下简称"信永中和会计师事 务所"）作为公司 2023 年度财务报表审计机构。根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司治理准则》《国有 企业、上市公司选聘会计师事务所管理办法》等规定和要求，公司对 信永中和会计师事务所在近一年审计中的履职情况进行了评估，具体 情况如下： 一、资质条件 （一）基本信息 名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日； 组织形式：特殊普通合伙企业； 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层； 首席合伙人：谭小青先生； 执业资格：具有财政部门颁发的会计师事务所执业资格，具有财 政部、中国证监会备案的从事证券服 ...